Seda ÇOLAK, Ahmet OMMA

Department of Rheumatology, Ankara Numune Training and Research Hospital, Ankara, Turkey

Keywords: Immune-related adverse events, nivolumab, seronegative arthritis

Abstract

Nivolumab is a monoclonal antibody against programmed cell death protein-1 which is assessed in the group of immune checkpoint inhibitors. It may lead to immune-related adverse events. In this article, we report a 38-year-old male patient diagnosed with seronegative arthritis after nivolumab therapy. This case supports that clinicians should be attentive for immune-related adverse events after use of immune checkpoint inhibitors.